panadiplon

Known as: 3-(5-cyclopropyl-1,2,4-oxadiazol 3-yl)-5-(1-methylethyl)imidazo(1,5-a)quinoxalin-4(5H)-one 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1995-2012
01219952012

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
The damage hit without warning. Of the 40 healthy volunteers who had enrolled in a Phase I trial for panadiplon, an experimental… (More)
Is this relevant?
Review
2009
Review
2009
Adverse drug reactions appear during the clinical use of a drug and constitute a health problem, as they are an important cause… (More)
Is this relevant?
2005
2005
Ethanol's ability to enhance GABA neurotransmission via GABA(A) receptors has been implicated as an important mechanism… (More)
Is this relevant?
2002
2002
5-ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahydrobenzo[4,5] imidazo[1,2a]pyridine-4-N-(2-fluorophenyl)carboxamide) (RWJ-51204… (More)
Is this relevant?
Review
2001
Review
2001
Preclinical drug safety evaluation studies, typically conducted in two or more animal species, reveal and define dose-dependent… (More)
Is this relevant?
2001
2001
The pentobarbital-like discriminative stimulus effects of the benzodiazepine receptor partial agonist panadiplon were assessed in… (More)
Is this relevant?
1999
1999
Purpose. To develop an integrated absorption model for estimating the fraction of dose absorbed and determining the causes of… (More)
Is this relevant?
1998
1998
The quinoxalinone anxiolytic, panadiplon, was dropped from clinical development due to unexpected hepatic toxicity in human… (More)
Is this relevant?
1996
1996
The quinoxalinone anxiolytic, panadiplon, produces hepatic metabolic inhibition (mitochondrial impairment), microvesicular… (More)
Is this relevant?
1995
1995
The non-benzodiazepine anxiolytic, panadiplon, was discontinued from clinical development due to evidence of hepatic toxicity in… (More)
Is this relevant?